TG Therapeutics (NASDAQ:TGTX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. TD Cowen assumed coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. Finally, HC Wainwright boosted their price objective on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Up 2.8 %

NASDAQ:TGTX opened at $28.77 on Tuesday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a fifty day simple moving average of $31.45 and a 200-day simple moving average of $25.28. TG Therapeutics has a 12 month low of $12.84 and a 12 month high of $36.84. The company has a market capitalization of $4.48 billion, a P/E ratio of -287.67 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter in the previous year, the firm posted $0.73 EPS. The firm’s revenue for the quarter was down 49.4% compared to the same quarter last year. On average, equities research analysts anticipate that TG Therapeutics will post 0.17 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,358 shares of company stock worth $781,497. Company insiders own 10.50% of the company’s stock.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TGTX. NBC Securities Inc. increased its stake in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics during the second quarter worth approximately $35,000. Blue Trust Inc. raised its stake in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in TG Therapeutics in the 3rd quarter valued at $53,000. Finally, Values First Advisors Inc. acquired a new stake in TG Therapeutics during the 3rd quarter worth $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.